637 related articles for article (PubMed ID: 30361246)
1. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
Ndjeka N; Schnippel K; Master I; Meintjes G; Maartens G; Romero R; Padanilam X; Enwerem M; Chotoo S; Singh N; Hughes J; Variava E; Ferreira H; Te Riele J; Ismail N; Mohr E; Bantubani N; Conradie F
Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30361246
[TBL] [Abstract][Full Text] [Related]
2. Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa.
Olayanju O; Limberis J; Esmail A; Oelofse S; Gina P; Pietersen E; Fadul M; Warren R; Dheda K
Eur Respir J; 2018 May; 51(5):. PubMed ID: 29700106
[TBL] [Abstract][Full Text] [Related]
3. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis.
Ndjeka N; Conradie F; Schnippel K; Hughes J; Bantubani N; Ferreira H; Maartens G; Mametja D; Meintjes G; Padanilam X; Variava E; Pym A; Pillay Y
Int J Tuberc Lung Dis; 2015 Aug; 19(8):979-85. PubMed ID: 26162365
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
Borisov SE; Dheda K; Enwerem M; Romero Leyet R; D'Ambrosio L; Centis R; Sotgiu G; Tiberi S; Alffenaar JW; Maryandyshev A; Belilovski E; Ganatra S; Skrahina A; Akkerman O; Aleksa A; Amale R; Artsukevich J; Bruchfeld J; Caminero JA; Carpena Martinez I; Codecasa L; Dalcolmo M; Denholm J; Douglas P; Duarte R; Esmail A; Fadul M; Filippov A; Davies Forsman L; Gaga M; Garcia-Fuertes JA; García-García JM; Gualano G; Jonsson J; Kunst H; Lau JS; Lazaro Mastrapa B; Teran Troya JL; Manga S; Manika K; González Montaner P; Mullerpattan J; Oelofse S; Ortelli M; Palmero DJ; Palmieri F; Papalia A; Papavasileiou A; Payen MC; Pontali E; Robalo Cordeiro C; Saderi L; Sadutshang TD; Sanukevich T; Solodovnikova V; Spanevello A; Topgyal S; Toscanini F; Tramontana AR; Udwadia ZF; Viggiani P; White V; Zumla A; Migliori GB
Eur Respir J; 2017 May; 49(5):. PubMed ID: 28529205
[TBL] [Abstract][Full Text] [Related]
5. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P
Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
[No Abstract] [Full Text] [Related]
7. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
Pym AS; Diacon AH; Tang SJ; Conradie F; Danilovits M; Chuchottaworn C; Vasilyeva I; Andries K; Bakare N; De Marez T; Haxaire-Theeuwes M; Lounis N; Meyvisch P; Van Baelen B; van Heeswijk RP; Dannemann B;
Eur Respir J; 2016 Feb; 47(2):564-74. PubMed ID: 26647431
[TBL] [Abstract][Full Text] [Related]
8. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N
BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcomes of pre- and extensively drug-resistant tuberculosis in Johannesburg, South Africa.
Nkurunziza J; Karstaedt AS; Louw R; Padanilam X
Int J Tuberc Lung Dis; 2018 Dec; 22(12):1469-1474. PubMed ID: 30606319
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study.
Brust JCM; Gandhi NR; Wasserman S; Maartens G; Omar SV; Ismail NA; Campbell A; Joseph L; Hahn A; Allana S; Hernandez-Romieu AC; Zhang C; Mlisana K; Viljoen CA; Zalta B; Ebrahim I; Franczek M; Master I; Ramangoaela L; Te Riele J; Meintjes G
Clin Infect Dis; 2021 Dec; 73(11):2083-2092. PubMed ID: 33882121
[TBL] [Abstract][Full Text] [Related]
11. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda.
Kabahita JM; Kabugo J; Kakooza F; Adam I; Guido O; Byabajungu H; Namutebi J; Namaganda MM; Lutaaya P; Otim J; Kakembo FE; Kanyerezi S; Nabisubi P; Sserwadda I; Kasule GW; Nakato H; Musisi K; Oola D; Joloba ML; Mboowa G
Antimicrob Resist Infect Control; 2022 May; 11(1):68. PubMed ID: 35550202
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis.
Guglielmetti L; Jaspard M; Le Dû D; Lachâtre M; Marigot-Outtandy D; Bernard C; Veziris N; Robert J; Yazdanpanah Y; Caumes E; Fréchet-Jachym M;
Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28182570
[TBL] [Abstract][Full Text] [Related]
13. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
Conradie F; Diacon AH; Ngubane N; Howell P; Everitt D; Crook AM; Mendel CM; Egizi E; Moreira J; Timm J; McHugh TD; Wills GH; Bateson A; Hunt R; Van Niekerk C; Li M; Olugbosi M; Spigelman M;
N Engl J Med; 2020 Mar; 382(10):893-902. PubMed ID: 32130813
[TBL] [Abstract][Full Text] [Related]
15. Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety.
Gao JT; Du J; Wu GH; Pei Y; Gao MQ; Martinez L; Fan L; Chen W; Xie L; Chen Y; Wang H; Jin L; Li GB; Zong PL; Xiong Y; Wu QH; Li MW; Yan XF; Miao YF; Cai QS; Li XJ; Bai DP; Geng SJ; Yang GL; Tang PJ; Zeng Y; Chen XH; Li TX; Cai C; Zhou Y; Zhuo M; Wang JY; Guan WL; Xu L; Shi JC; Shu W; Cheng LL; Teng F; Ning YJ; Xie SH; Sun YX; Zhang LJ; Liu YH
Infect Dis Poverty; 2021 Mar; 10(1):32. PubMed ID: 33736710
[TBL] [Abstract][Full Text] [Related]
16. Evidence-based Definition for Extensively Drug-Resistant Tuberculosis.
Roelens M; Battista Migliori G; Rozanova L; Estill J; Campbell JR; Cegielski JP; Tiberi S; Palmero D; Fox GJ; Guglielmetti L; Sotgiu G; Brust JCM; Bang D; Lienhardt C; Lange C; Menzies D; Keiser O; Raviglione M
Am J Respir Crit Care Med; 2021 Sep; 204(6):713-722. PubMed ID: 34107231
[No Abstract] [Full Text] [Related]
17. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
Dheda K; Cox H; Esmail A; Wasserman S; Chang KC; Lange C
Respirology; 2018 Jan; 23(1):36-45. PubMed ID: 28850767
[TBL] [Abstract][Full Text] [Related]
18. Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman.
Jaspard M; Elefant-Amoura E; Melonio I; De Montgolfier I; Veziris N; Caumes E
Emerg Infect Dis; 2017 Oct; 23(10):1731-2. PubMed ID: 28792382
[TBL] [Abstract][Full Text] [Related]
19.
Pang Y; Zong Z; Huo F; Jing W; Ma Y; Dong L; Li Y; Zhao L; Fu Y; Huang H
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739779
[TBL] [Abstract][Full Text] [Related]
20. A four-drug standardized short regimen for highly resistant TB in South-West Nigeria.
Fadeyi MO; Decroo T; Ortuño-Gutiérrez N; Ahmed B; Jinadu A; El-Tayeb O; Adebola W; Kehinde A; Lynen L; Gils T
Int Health; 2024 Jan; 16(1):123-125. PubMed ID: 37026448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
